How did lurbinectedin exposure affect fetal development?

How did lurbinectedin reach the fetus in animal studies?
Lurbinectedin crossed the placental barrier in rats and rabbits, producing measurable drug levels in fetal tissues after maternal dosing.

What birth defects appeared in rat and rabbit fetuses?
Exposed fetuses showed increased rates of skeletal malformations, external abnormalities, and reduced fetal body weight compared with unexposed controls.

Did the effects depend on dose and timing?
Malformations and growth reduction occurred mainly at doses that also caused maternal toxicity and during organogenesis, the period of greatest fetal sensitivity.

How does this compare with other DNA-damaging oncology drugs?
Similar patterns of embryofetal toxicity have been reported for other alkylating agents used in cancer treatment, suggesting a shared mechanism of DNA damage during rapid cell division.

What do the findings imply for human pregnancy?
No controlled human data exist, but the animal results support current recommendations to avoid lurbinectedin in pregnant patients and to require effective contraception during and after treatment.

When does the drug’s label advise contraception use?
Women of reproductive potential are instructed to use effective contraception during therapy and for at least six months afterward; men with female partners should use contraception for four months after the last dose.

Are biosimilars or alternative agents under development?
No biosimilars of lurbinectedin are approved, and alternative therapies for relapsed small-cell lung cancer remain limited, keeping the drug’s risk–benefit profile under ongoing regulatory review.